Möchten Sie immer auf dem neuesten Stand bleiben?

Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.

Beim Leserkonto Anmelden Leserkonto Erstellen

29. Januar 2020 10:00 ET | Quelle: Innovation Pharmaceuticals Inc.

Innovation Pharmaceuticals Further Engages Locust Walk to Lead Out-Licensing Negotiations for Rights to Phase 3-Ready Oral Mucositis Drug Candidate

WAKEFIELD, Mass., Jan. 29, 2020 (GLOBE NEWSWIRE) -- Innovation Pharmaceuticals Inc. (OTCQB:IPIX) (“the Company”), a clinical stage biopharmaceutical company, has further engaged Locust Walk, a...
24. Januar 2020 11:30 ET | Quelle: Innovation Pharmaceuticals Inc.

Innovation Pharmaceuticals Completes Dosing in Phase 1 Trial for New Oral Ulcerative Colitis Drug

WAKEFIELD, Mass., Jan. 24, 2020 (GLOBE NEWSWIRE) -- Innovation Pharmaceuticals (OTCQB:IPIX) (“the Company”), a clinical stage pharmaceutical company, announced today the Company completed dosing in...
17. Januar 2020 08:30 ET | Quelle: Innovation Pharmaceuticals Inc.

Innovation Pharmaceuticals Announces Dose Escalation

WAKEFIELD, Mass., Jan. 17, 2020 (GLOBE NEWSWIRE) -- Innovation Pharmaceuticals (OTCQB:IPIX) (“the Company”), a clinical stage pharmaceutical company, announced today that the Company has received...
16. Januar 2020 12:00 ET | Quelle: Innovation Pharmaceuticals Inc.

Innovation Pharmaceuticals Announces Dosing of First Cohort in Phase 1 Trial of Oral Brilacidin in Ulcerative Colitis Program; Topline Results Anticipated Early Q1 2020

WAKEFIELD, Mass., Jan. 16, 2020 (GLOBE NEWSWIRE) -- Innovation Pharmaceuticals (OTCQB:IPIX) (“the Company”), a clinical stage pharmaceutical company, is pleased to inform shareholders that the...
26. Dezember 2019 08:00 ET | Quelle: Innovation Pharmaceuticals, Inc.

Innovation Pharmaceuticals: Patient Screening for Phase 1 Trial of Oral Brilacidin in Ulcerative Colitis Program On Track for Early January

Patient screening positions Company for completion of a short clinical trialSignificant market demand for oral drugs in Inflammatory Bowel DiseaseBusiness development meetings scheduled during 2020...
13. Dezember 2019 09:30 ET | Quelle: Innovation Pharmaceuticals, Inc.

Innovation Pharmaceuticals Granted Regulatory Approval to Start Phase 1 Trial of Oral Brilacidin in Ulcerative Colitis Program; Company Aims to Capture Large Market Opportunity for Novel Oral IBD Drug Candidates

BEVERLY, Mass., Dec. 13, 2019 (GLOBE NEWSWIRE) -- Innovation Pharmaceuticals (OTCQB:IPIX) (“the Company”), a clinical stage pharmaceutical company, is pleased to inform shareholders that the United...
10. Dezember 2019 09:30 ET | Quelle: Innovation Pharmaceuticals, Inc.

Innovation Pharmaceuticals Provides Update on Clinical Trials and Revenue Potential of Brilacidin in Inflammatory Bowel Diseases

Targeting mid-year 2020 to commence clinical trials of Brilacidin for UP/UPS indicationRegulatory documents submitted to health authorities for planned Ulcerative Colitis study BEVERLY, Mass., Dec....
25. November 2019 09:30 ET | Quelle: Innovation Pharmaceuticals, Inc.

Innovation Pharmaceuticals and FDA Agree to Waive Initial Pediatric Study Plan Requirement Regarding Brilacidin for the Prevention of Oral Mucositis

BEVERLY, Mass., Nov. 25, 2019 (GLOBE NEWSWIRE) -- Innovation Pharmaceuticals (OTCQB:IPIX) (“the Company”), a clinical stage pharmaceutical company, is pleased to inform shareholders the Company...
13. November 2019 08:30 ET | Quelle: Innovation Pharmaceuticals, Inc.

Innovation Pharmaceuticals: Oral Cancer on the Rise; Company Offers Perspectives on Opportunity of Brilacidin for the Prevention of Oral Mucositis

Oral cancer incidence increasing worldwide due to spread of human papillomavirus (HPV), Oral SexMillions of patients worldwide suffer from treatment-induced Oral Mucositis (OM)Existing OM therapies...
28. Oktober 2019 09:30 ET | Quelle: Innovation Pharmaceuticals, Inc.

Innovation Pharmaceuticals Highlights Preclinical Data by Independent Cancer Researchers Supporting p53 Drug Candidate Kevetrin’s Potential in Treating Acute Myeloid Leukemia

BEVERLY, Mass., Oct. 28, 2019 (GLOBE NEWSWIRE) -- Innovation Pharmaceuticals (OTCQB:IPIX) (“the Company”), a clinical stage biopharmaceutical company, is pleased to highlight preclinical data by...

Vorherige Seite